Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Status:
Completed
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the safety and activity of regorafenib in
participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved
therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug
that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important
to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both
imatinib and sunitinib work; however, regorafenib blocks certain additional signaling
pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested
in GIST participants before this research study.
Phase:
Phase 2
Details
Lead Sponsor:
Suzanne George, MD
Collaborators:
Bayer Brigham and Women's Hospital Fox Chase Cancer Center Massachusetts General Hospital Oregon Health and Science University